Recent Headlines
AnaSpec Offers Special Pricing for MOG (1-125) Recombinant Proteins
AnaSpec, EGT the first provider of commercial MOG recombinant proteins is pleased to offer a 50% discount off on MOG (1-125) recombinant proteins through the month of February, 2012 to US and Canadian customers. Please mention code “rMOG50%” when ordering to get the discount. AnaSpec's... - February 16, 2012 - AnaSpec, EGT Group
Milton Boyer Named President of OSO BioPharmaceuticals Manufacturing
Boyer has been responsible for guiding business strategies and creating new growth opportunities at OsoBio since 2008 - February 15, 2012 - OSO BioPharmaceuticals Manufacturing, LLC
AnaSpec Introduces SensoLyte® Factor Xa Activity Assays – Industry’s First Fluorimetric Kits
AnaSpec, EGT Group is pleased to announce the release of the industry first fluorimetric Factor Xa activity assays - The SensoLyte® 520 Factor Xa Assay Kit and the SensoLyte® Rh110 Factor Xa Assay Kit. The SensoLyte® 520 Factor Xa Assay Kit employs a FRET (5-FAM/QXL™ 520)... - February 15, 2012 - AnaSpec, EGT Group
SFL’s Managing Director to Speak at Healthcare Businesswomen’s Association Event
SFL is pleased to announce that Shayesteh Fürst-Ladani, Managing Director of the company, will be speaking at the upcoming Healthcare Businesswomen’s Association European meeting entitled “The Role of Regulatory Affairs in Successful Development and Launch of Healthcare Products” to be held in Basel, Switzerland. - February 09, 2012 - SFL Regulatory Affairs & Scientific Communication Ltd
AnaSpec Offers Antibodies Against the Hexa-His and GFP Tags
The introduction of tags, whether short peptides (6X-His, DYKDDDDK, c-myc) or proteins (green fluorescent protein – GFP, glutathione-s-transferase – GST) into recombinant proteins aids in the characterization, localization or purification of the recombinant expressed protein.1-3 As a... - February 03, 2012 - AnaSpec, EGT Group
AnaSpec Highlights Calcein AM for Live Cell Staining
Calcein AM (Calcein acetoxymethyl ester), a non-fluorescent, cell permeable compound, converts to the strongly green fluorescent calcein when hydrolyzed by intracellular esterases in live cells.1-2 It is widely used for determining cell viability since the fluorescence intensity of calcein is... - February 02, 2012 - AnaSpec, EGT Group
AnaSpec Highlights Atrial Natriuretic Peptides in GO® Collection
AnaSpec, EGT Group provides a wide range of GO® (catalog) natriuretic peptides for use in research laboratories. Their selection of atrial natriuretic peptides (ANPs) include the biologically active 1-28 amino acid peptide (human/porcine or rat sequences); shorter ANP fragments; and Biotin, FAM... - February 02, 2012 - AnaSpec, EGT Group
Advanced Cancer Therapeutics Chief Scientific Officer to Present Preclinical Data on Glycolysis Inhibitors at World Cancer Metabolism Summit
Advanced Cancer Therapeutics, LLC (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that Dr. Gilles Tapolsky, ACT’s Chief Scientific Officer, has been selected to present at the World Cancer Metabolism Summit to be held February 1 – February 2, 2012 in Washington, D.C. - February 01, 2012 - Advanced Cancer Therapeutics
Novus Biologicals Added as New Preferred Vendor for the University of Washington
Novus Biologicals is excited to be a preferred vendor for the University of Washington. Novus’ extensive product line will soon be added to the UW online ordering system, and all UW researchers will now receive 5% off any order. Novus Biologicals is committed to developing and maintaining... - January 28, 2012 - Novus Biologicals
AnaSpec Offers Speedy 28-Day Custom Polyclonal Antibody Service
When traditional protocols can take almost 90 days, the wait for high-quality custom polyclonal antibodies can be excruciating. AnaSpec is pleased to introduce the Speedy 28-day custom polyclonal antibody service. Leveraging proven technology from Eurogentec, AnaSpec's parent company, this protocol... - January 25, 2012 - AnaSpec, EGT Group
AnaSpec Introduces SensoLyte® α-Synuclein ELISA Assay
AnaSpec, EGT Group is pleased to announce the release of an ultrasensitive ELISA assay for quantitatingα-synuclein. The SensoLyte® α-Synuclein Quantitative ELISA Kit (Human/Mouse/Rat) provides a convenient and quantitative assay for determining α-Synuclein amount in cell and... - January 25, 2012 - AnaSpec, EGT Group
AnaSpec Expands SensoLyte® 520 Renin Assay Kits Collection
AnaSpec, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit now provides renin kits specific for mouse and rat - the SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit. Using their proprietary 5-FAM/QXL™ 520 fluorescence resonance... - January 25, 2012 - AnaSpec, EGT Group
AnaSpec Introduces Ultra-Sensitive SensoLyte® NADP/NADPH Assay Kit
AnaSpec, EGT Group, the provider of ultra-sensitive fluorimetric SensoLyte® line of assay kits is pleased to announce the release of the SensoLyte® Fluorimetric NADP/NADPH Assay Kit. This assay is a sensitive fluorimetric assay that detects NADP and NADPH without interfering with NAD/NADH. - January 19, 2012 - AnaSpec, EGT Group
AnaSpec Includes Ghrelin and Obestatin Peptides in GO® Collection
AnaSpec, EGT Group, a leading provider of integrated proteomic and genomic solutions, offers a wide range of ghrelin and obestatin GO® (catalog) peptides for research use. In 1999, Kojima and his group (1) reported the discovery of a growth hormone secretagogue that is involved in the release... - January 19, 2012 - AnaSpec, EGT Group
AnaSpec Highlights Its Proprietary HiLyte Fluor™ Dye Collection
AnaSpec, EGT Group’s proprietary HiLyte Fluor™ dyes are a series of excellent fluorescent labeling dyes with fluorescence emissions that span the full visible and near infrared spectrum. The hydrophilic property of most of the HiLyte Fluor™ dyes makes conjugations to protein... - January 17, 2012 - AnaSpec, EGT Group
CrystalGenomics Scores KRW 3 Billion in Strategic Equity Investment from KSLSF, a Life Science Fund Backed by the City of Seoul and the Ministry of Knowledge Economy
CrystalGenomics, Inc. (KOSDAQ: CRYSTAL [083790]), a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has successfully raised KRW 3 Billion (USD 2.6 Million) in a private placement to the Korea Seoul Life Science Fund (KSLSF). This is the third time within... - January 16, 2012 - CrystalGenomics, Inc.
John Quackenbush to Speak at CHI’s Bioinformatics & Cancerinformatics Conference, February 21-23, San Francisco, CA
Dr. Quackenbush will present in the translating biomarker driven cancer treatments into practice session. - January 12, 2012 - Cambridge Healthtech Institute
SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning). - January 12, 2012 - SignaBlok, Inc.
Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference
Aciont Inc. announced today that both Kongnara Papangkorn, Research Director and Sarah Abdulla Molokhia, Scientific Research Consultant, will present on Aciont’s Visulex technologies at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012,... - January 12, 2012 - Aciont Inc.
Autoscribe Launches US Operation
The formation of Autoscribe Informatics Inc., a wholly owned subsidiary of Autoscribe Ltd, has been announced. Based in Falmouth, MA, USA, it gives Autoscribe, the developers of Matrix software products, a much stronger presence in the US and Canadian markets. Zumatrix Inc. operated as... - January 12, 2012 - Autoscribe Informatics
CrystalGenomics to Present at J.P. Morgan Healthcare Conference on January 12
CrystalGenomics, Inc. (KOSDAQ: CRYSTAL (083790)), a clinical stage biopharmaceutical company headquartered in Korea, has just announced that Joong Myung Cho, Ph.D., President & CEO, will present an overview of CrystalGenomics’ business strategy and an update on its development pipeline on... - January 11, 2012 - CrystalGenomics, Inc.
Declan Doogan of Amarin to Keynote CHI’s Conference on Phase III Clinical Trials
Amarin’s CMO to lead line-up of thought leaders at Cambridge Healthtech Institute’s executive and scientific forum. - December 26, 2011 - Cambridge Healthtech Institute
AnaSpec Highlights HiLyte Fluor™ Dyes Collection - for Labeling Amine and Thiol-Modified Oligos
AnaSpec is pleased to highlight their wide collection of amine and thiol reactive 6-isomeric dyes of fluoresceins and rhodamines, and AnaSpec’s own proprietary HiLyte Fluor™ dyes for labeling amine and thiol modified oligonucleotides. Fluorescent dye-labeled oligos are widely used as... - December 21, 2011 - AnaSpec, EGT Group
TransEnterix Closes $15M in Equity Financing
Second tranche of Series B to accelerate development and commercialization of new flexible surgical tools - December 18, 2011 - TransEnterix
New Lightning-Link® Rapid Antibody Labeling Kits Now for DyLight™ Dyes
The Lightning-Link® Rapid Antibody kits allow direct antibody labeling reactions to be set up in seconds and used within just 20 minutes. Novus has recently expanded their Lighting-Link® Rapid kits to include the following DyLight™ dyes. Lightning-Link® Rapid DyLight... - December 17, 2011 - Novus Biologicals
Novus New Lab Program - Receive 20% Off for New Labs
Novus Biologicals understands the funding constraints and logistical difficulties of starting a new lab. Therefore, Novus is proud to announce a New Lab Program, offering 20% off Novus purchases for your first 3 months. Additionally, Novus will provide a welcome kit full of useful tools for your... - December 16, 2011 - Novus Biologicals
Novus Products Now Available Through the UPENN Cell Center Stockroom
Novus is proud to announce that select products will now be available through the University of Pennsylvania’s Cell Center Stockroom. Researchers who order through the Cell Center Stockroom will receive a 20% discount off the regular list price and free shipping. The Cell Center Stockroom... - December 15, 2011 - Novus Biologicals
SFL’s Public Affairs Now Covers Bioethics
SFL’s Public Affairs team, helping organizations shape EU rules, saw exciting expansion in 2011. - December 11, 2011 - SFL Regulatory Affairs & Scientific Communication Ltd
SFL Thanks Clients and Partners for Successful Collaborations
With the end of 2011 approaching, SFL can reflect on a very successful year of extension and expansion in all areas. The company’s client base has expanded internationally as demand has grown for its personalized and comprehensive services in the fields of Regulatory Affairs, Public Affairs, Legal Services and Medical Communication. - December 08, 2011 - SFL Regulatory Affairs & Scientific Communication Ltd
Mitegen Announces Distribution Agreement with Helix Biotech in Malaysia
Mitegen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed a distribution agreement with Helix Biotech (M) SDN BHD of... - November 12, 2011 - MiTeGen, LLC
Mitegen Announces Mutual Distribution Agreements with AJK Analytical Services
Mitegen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed mutual distribution agreements with AJK Analytical Services. - November 12, 2011 - MiTeGen, LLC
Novus Biologicals Announces New ROBLD3 Antibody Made Using SDIX Genomic Antibody Technology™
Novus Biologicals announced today a new ROBLD3 antibody (catalog number NBP1-71687) for use in research on cell growth regulation. This ROBLD3 antibody was made using SDIX Genomic Antibody TechnologyTM. ROBLD3 is one of three individual proteins (ROBLD3, c11orf59 & MAPKSP1) that form the... - November 11, 2011 - Novus Biologicals
Introducing BioDatomics - the Latest Bioinformatics & Computational Biology Platform
BioDatomics releases a new version of their computational biology analysis and visualization platform – a workstation version is now available for free download. - November 10, 2011 - BioDatomics
RayBiotech, Inc. Engages Industry Expert for Business Development & Growth Advisory Services
RayBiotech, Inc., today announced that it has engaged recognized industry expert, David A. Dodd of RiversEdge BioVentures LLC to work with the Company in the areas of Business Development and Strategic Growth Opportunities. - November 10, 2011 - RayBiotech, Inc
Prevtec microbia Closes a $4 Million Financing Round with North-American and European Investors
Prevtec microbia inc., a rapidly expanding Canadian biotech company developing innovative animal health technologies for the livestock industry, announced that it has closed a $4 million financing round from a global syndicate of financial and industry leaders. The proceeds will mostly be used to... - November 09, 2011 - Prevtec microbia inc.
VP at OSO BioPharmaceuticals Elected to DCAT Board of Directors
Milton Boyer to serve three-year term at leading industry association. - November 03, 2011 - OSO BioPharmaceuticals Manufacturing, LLC
Mitegen Announces Mutual Distribution Agreements with XTalQuest Inc., Ltd.
Mitegen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed mutual distribution agreements with XTalQuest Inc., Ltd a Beijing based provider of high quality crystallization plates, screening solutions, and other products for crystallography. - November 01, 2011 - MiTeGen, LLC
Novus Biologicals Announces New CHD7 Antibody Made Using SDIX Genomic Antibody Technology™
Novus Biologicals announced today a new CHD7 antibody (catalog number NBP1-77393) for use in research on transcription regulation and CHARGE syndrome. This CHD7 antibody was made using SDIX Genomic Antibody TechnologyTM. CHD7 is an ATP-dependent chromatin remodeler that interacts closely with SOX2... - October 29, 2011 - Novus Biologicals
New LDL and VLDL Receptor Antibodies Released
Novus Biologicals announced today the release of new LDL Receptor (NBP1-78159) and VLDL Receptor (NBP1-78162) antibodies. LDL and VLDL Receptors are similar cell-surface receptor proteins which mediate endocytosis of cholesterol-rich lipoproteins. Both receptors are critical to the lipid and... - October 27, 2011 - Novus Biologicals
Novus Biologicals Announces New PAR1 Antibody
Novus Biologicals announced today a new Thrombin Receptor antibody (catalog number NBP1-71770) for use in wound healing and cancer research. Thrombin Receptor, also known as Protease activated receptor 1 (PAR1), is a G-protein-coupled receptor that functions in blood clotting. While Thrombin... - October 26, 2011 - Novus Biologicals
Novus Biologicals Announces New SHDA Antibody Made Using SDIX Genomic Antibody Technology™
Novus Biologicals announced today a new SDHA Antibody (catalog number NBP1-71688) for use in hypoxia research. This SHDA antibody was made using SDIX Genomic Antibody TechnologyTM. Localized within the mitochondrial inner membrane, Succinate Dehydrogenase A (SDHA) is an important component in the... - October 23, 2011 - Novus Biologicals
Advanced Cancer Therapeutics CEO to Present Preclinical Data on Cancer Metabolism Drug at MidAmerica Healthcare Venture Forum
Advanced Cancer Therapeutics, LLC (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that Randall B. Riggs, President & CEO, has been selected to present at the 9th Annual MidAmerica Healthcare Venture Forum to be held at the... - October 20, 2011 - Advanced Cancer Therapeutics
Novus Biologicals Announces New Dicer1 Antibody Made Using SDIX Genomic Antibody Technology™
Novus Biologicals announced today a new DICER1 antibody (catalog number NBP1-71691) for use in cell cycle and replication and cancer research. This DICER1 antibody was made using SDIX Genomic Antibody TechnologyTM. DICER1 is a ribonuclease that has been extensively shown to be related to cancer. - October 20, 2011 - Novus Biologicals
AnaSpec Introduces SensoLyte® Deubiquitination Assay Kit
AnaSpec, EGT Group, is pleased to introduce the SensoLyte® 440 Deubiquitination Assay Kit. This kit provides a convenient assay for inhibitors/activators screening in deubiquitinylation or for continuous assay of enzyme activity. A natural substrate, ubiquitin, coupled with the AMC... - October 19, 2011 - AnaSpec, EGT Group
AnaSpec Includes Citrullinated Histone in GO® Peptides Collection
AnaSpec, the world’s largest provider of on-demand GO® peptides is pleased to offer a wide selection of Histone H1, H2A, H2B, H3 and H4 peptides, especially the H3 peptides. The rapidly expanding Histone GO® Peptides now include citrullinated sequences in addition to sequences that... - October 19, 2011 - AnaSpec, EGT Group
Novus Focuses on Supplying Quality Antibodies for Model Organism Research
Novus is a leading supplier of research antibodies that have been validated for use in model organisms, and they have recently expanded their selection of top quality reagents for Drosophila melanogaster, Caenorhabditis elegans, and Xenopus laevis. These three model organisms are commonly used in... - October 15, 2011 - Novus Biologicals
MMS Announces Strategic Alliance with TransPerfect
MMS Holdings Inc. announces a strategic alliance with TransPerfect, the world's largest privately held provider of language services and technology, to offer translation and interpretation services to their clients across global clinical programs. These services are complimentary to those offered... - October 15, 2011 - MMS Holdings Inc.
Novus Announces Two Contest Winners
Novus Biologicals announced today the winners of two customer contests. First, the third quarter Novus Travel Grant winner is Dr. Toryn Poolman of the University of Manchester's School of Medicine, selected for his excellent review of our Glucocorticoid Receptor Antibody (NB300-610). Dr. Poolman... - October 14, 2011 - Novus Biologicals
New EpiPlus - Histone Modification Antibodies Announced Today
Novus Biologicals announced today the release of a new group of Epi-PlusTM antibodies for histone modification testing. Over the past several months, Novus has collaborated with 21st Century Biochemicals, a leading manufacturer of custom antibodies and peptides, to generate the most well validated... - October 12, 2011 - Novus Biologicals
Miami Surgery Practice Offers Discreet New STARR Weight-Loss Treatment
Bariatric surgeon Dr. Enrique Whittwell praises privacy and comfort of new procedure. - October 07, 2011 - TransEnterix